The reality id that it's doing down much more. It is a sad story and I wish I never owned this thing. The P3 trial is an open label trial (not double blinded), therefore, the company knew all along how much allovection shipped at any time, and thus how many patients were still being treated. They do have a rough idea of the efficacy in the last 3 years or so. However, there is absolutely no insider buying (except the over allotment by Singer at 3.75 in the secondary offer). That said something. I will get rid of everything I got and invest somewhere else.
VJ stressed everywhere that they recruited healthier patients and I guess that why the patients liver longer. Recent reviews show that stage III, IVa-b (low phosphatase) patients that median survival is over 2 years.